Suchergebnisse - "Spinner, Christoph D"

PubPharm (14)

1

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2) : results of a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Infectious diseases | 2022

von Hardt, K. | Vandebosch, A. | Sadoff, J. | +115

CommentIn: Lancet Infect Dis. 2022 Dec;22(12):1654-1655. - PMID 36113536

2

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022

von Spinner, C. | Felizarta, F. | Rizzardini, G. | +16

3

Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir : a DUALIS sub-study

enthalten in: AIDS care | 2022

von Olliges, E. | Bührlen, B. | Fischer, F. | +14

4

Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes

enthalten in: HIV research & clinical practice | 2021

von Monin, M. | Kümmerle, T. | Schneider, J. | +16

5

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

enthalten in: The Lancet. Respiratory medicine | 2021

von Marconi, V. | Ramanan, A. | de Bono, S. | +105

CommentIn: Lancet Respir Med. 2021 Dec;9(12):1349-1351. - PMID 34480862

6

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance

enthalten in: AIDS research and therapy | 2021

von Wolf, E. | Boesecke, C. | Balogh, A. | +9

7

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis : week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The lancet. HIV | 2021

von Ogbuagu, O. | Ruane, P. | Podzamczer, D. | +118

ErratumIn: Lancet HIV. 2021 Dec;8(12):e734. - PMID 34571044

8

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1

enthalten in: HIV research & clinical practice | 2020

von Huhn, G. | Wilkin, A. | Mussini, C. | +8

9

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

enthalten in: The New England journal of medicine | 2020

von Goldman, J. | Lye, D. | Hui, D. | +71

CommentIn: N Engl J Med. 2020 Nov 5;383(19):1886-1887. - PMID 32459913

10

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 : A Randomized Clinical Trial

enthalten in: JAMA | 2020

von Spinner, C. | Gottlieb, R. | Criner, G. | +28

CommentIn: JAMA. 2020 Sep 15;324(11):1041-1042. - PMID 32821934